Healthcare costs

Findings from a nationally representative US survey show that a substantial minority of people with diabetes ration their use of insulin because of issues with affordability.

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

Reducing the cost of SGLT2 inhibitors by around 17% would make them cost-effective for use in people with type 2 diabetes in low- and middle-income countries, study findings indicate.

Adding canagliflozin to current standard of care improves survival, increases quality-adjusted life–years, and reduces treatment costs for people with type 2 diabetes treated in England over a 10-year period, research suggests.

Compulsory enrollment in a high-deductible health insurance plan is associated with significant delays in seeking care for macrovascular complications among people with diabetes, US research shows.